BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR
- In addition to STK11 mutations, KEAP1m identified as being associated with STK11 loss of function - - STK11 loss of function correlated to AXL activation and poorer outcomes in NSCLC - BERGEN, Norway, April 18, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that it presented data linking AXL activation to STK11 loss of function in Non-Small Cell Lung Cancer (NSCLC) in an abstract titled, AXL as a Therapeutic Target in STK11 mutant NSCLC, at the